Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

Redeye: Acconeer - Short-Term Weakness but Long-Term View Intact

Acconeer

Redeye states that the Q1 report was a disappointment in terms of financial figures - with both sales and the number of customer launches well below Redeye's expectations. Redeye does, however, not change its perception about where Acconeer will be a few years out. While the road from cSEK10m to above SEK100m revenues per quarter is steep, there will inevitably be bumps on the road to get there. Redeye thinks Q1 was one such bump. Additionally, Redeye estimates that Acconeer will need additional financial of SEk100-150m in H2'23. Redeye makes minor adjustments to its fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Acconeer - Short-Term Weakness but Long-Term View Intact

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.